Pulse Biosciences (NASDAQ:PLSE) Shares Up 7.6% - What's Next?

Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) were up 7.6% during mid-day trading on Friday . The stock traded as high as $20.89 and last traded at $21.15. Approximately 90,376 shares changed hands during mid-day trading, a decline of 26% from the average daily volume of 121,426 shares. The stock had previously closed at $19.66.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised Pulse Biosciences to a "sell" rating in a report on Thursday, January 2nd.

Pulse Biosciences Stock Performance

The business's fifty day moving average price is $18.74 and its 200-day moving average price is $17.84.

Insider Activity

In other Pulse Biosciences news, Director Robert W. Duggan acquired 55,256 shares of the business's stock in a transaction dated Friday, December 13th. The stock was purchased at an average price of $17.18 per share, with a total value of $949,298.08. Following the transaction, the director now directly owns 42,328,717 shares in the company, valued at approximately $727,207,358.06. The trade was a 0.13 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Burke Thomas Barrett sold 50,000 shares of Pulse Biosciences stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total value of $871,000.00. Following the transaction, the chief executive officer now owns 63,172 shares in the company, valued at $1,100,456.24. This trade represents a 44.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 71.50% of the company's stock.

Institutional Trading of Pulse Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Creative Planning boosted its position in shares of Pulse Biosciences by 113.9% during the third quarter. Creative Planning now owns 21,910 shares of the company's stock worth $384,000 after acquiring an additional 11,667 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Pulse Biosciences by 193.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company's stock worth $2,598,000 after purchasing an additional 97,565 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Pulse Biosciences during the 3rd quarter valued at about $588,000. State Street Corp grew its position in shares of Pulse Biosciences by 17.8% during the third quarter. State Street Corp now owns 461,333 shares of the company's stock valued at $8,092,000 after purchasing an additional 69,696 shares in the last quarter. Finally, Barclays PLC increased its holdings in shares of Pulse Biosciences by 361.4% in the third quarter. Barclays PLC now owns 30,306 shares of the company's stock worth $530,000 after purchasing an additional 23,738 shares during the last quarter. Institutional investors own 76.95% of the company's stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.